Waitzberg Dan L, Quilici Flávio A, Michzputen Sender, Friche Passos Maria do Carmo
University of Sao Paulo, School of Medicine, Gastroenterology Department, LIM 35, Sao Paulo..
University Catholic of Campinas, School of Medicine, Digestive Surgery Department. Campinas, SP..
Nutr Hosp. 2015 Aug 1;32(2):501-9. doi: 10.3305/nh.2015.32.2.9232.
AIM: determine the effectiveness of fermented milk that included Bifidobacterium lactis CNCM I-2429 for reducing gastrointestinal (GI) discomfort in healthy adults. METHODS: we conducted a systematic literature search to identify studies reporting the use of B. animalis spp. lactis for GI discomfort/comfort in healthy adults. A total of 5329 records were identified, of these 99 full-text articles were assessed. Searches for additional trials were conducted using the names of authors of each identified study and several relevant databases. The study selection was carried out according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies were included if they were randomized controlled trials; the included subjects were healthy adults; and the intervention group received B. lactis CNCM I-2494. Studies were excluded if they were non-randomized trials, if they included adults who were not healthy, if they included the use of any other intervention, or if they compared different products without a placebo group. The methodological quality of the studies was evaluated using the Oxford Quality Scale and the Cochrane Concealment Assessment. A meta-analysis was not possible. RESULTS: the search strategy identified two studies that included a total of 538 healthy women, aged 18-60 years, normal weight or overweight (BMI 18-30 kg/m2). GI well-being was significantly improved in the Probiotic group vs. the Control group in one study, with no differences in the other. The percentage of responders for GI well-being was higher in the Probiotic group vs. the Control group in the first study but not in the second. GI symptoms were significantly decreased in the Probiotic group vs. the Control group in both studies. Bowel function was assessed by one study; the stool frequency did not differ between the groups, but a decrease in stool consistency was observed in the Probiotic group but not in the Control group. Possible mechanisms of action (gut motility, hypersensitivity, gut permeability, and gut microbiota) were also described. CONCLUSION: probiotic fermented milk containing B. lactis CNCM I-2494 by healthy women may improve GI well- being and decrease the frequency of GI symptoms.
目的：确定含有乳酸双歧杆菌CNCM I - 2429的发酵乳对减轻健康成年人胃肠道（GI）不适的有效性。 方法：我们进行了一项系统的文献检索，以找出报告使用动物双歧杆菌亚种乳酸亚种来改善健康成年人胃肠道不适/舒适度的研究。共识别出5329条记录，其中99篇全文文章被评估。使用每篇已识别研究的作者姓名和几个相关数据库进行额外试验的搜索。研究选择按照系统评价和Meta分析的首选报告项目（PRISMA）指南进行。如果研究是随机对照试验；纳入的受试者是健康成年人；干预组接受乳酸双歧杆菌CNCM I - 2494，则纳入该研究。如果研究是非随机试验、纳入了不健康的成年人、使用了任何其他干预措施，或者比较了不同产品但没有安慰剂组，则排除该研究。使用牛津质量量表和Cochrane隐匿评估来评估研究的方法学质量。无法进行Meta分析。 结果：检索策略识别出两项研究，共纳入538名18 - 60岁、体重正常或超重（BMI 18 - 30 kg/m²）的健康女性。在一项研究中，益生菌组与对照组相比，胃肠道健康状况有显著改善，另一项研究中则无差异。在第一项研究中，益生菌组胃肠道健康状况的应答者百分比高于对照组，但第二项研究中并非如此。在两项研究中，益生菌组与对照组相比，胃肠道症状均显著减少。一项研究评估了肠道功能；两组之间的排便频率没有差异，但在益生菌组中观察到粪便稠度降低，而对照组中未观察到。还描述了可能的作用机制（肠道蠕动、超敏反应、肠道通透性和肠道微生物群）。 结论：健康女性食用含有乳酸双歧杆菌CNCM I - 2494的益生菌发酵乳可能改善胃肠道健康状况并减少胃肠道症状的发生频率。
Probiotics Antimicrob Proteins. 2025-6
Microorganisms. 2023-10-5
Appl Environ Microbiol. 2019-3-22
Zotero 插件